Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZURE study of elenestinib in advanced systemic mastocytosis and other KIT-altered hematologic malignancies
NL-OMON59340Phase 2Completed
- Sponsor
- Blueprint Medicines
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of elenestinib and azacitidine in systemic mastocytosis (SM) and hematopoietic malignancies (2 arms), sponsored by Blueprint Medicines. Primary endpoints: Recommended dose determination for monotherapy, Safety and tolerability of monotherapy and 3 more. Started Mar 2024; status: completed.
02
Drugs
elenestinibazacitidine
03
Conditions
systemic mastocytosis (SM)hematopoietic malignancies
Beyond the preview
Go deeper on NL-OMON59340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59340.